<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630539</url>
  </required_header>
  <id_info>
    <org_study_id>15-50717</org_study_id>
    <nct_id>NCT00630539</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women</brief_title>
  <official_title>Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A Phase II Dose Ranging, 12-Week, Randomized , Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 5 mg, 15 mg and 30 mg Daily Doses With Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hormos Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>QuatRx Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shionogi Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5
      mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum
      effective dose below the lowest dose of 30 mg tested earlier in Phase II.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of the Vaginal Smear</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Vaginal pH</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Evaluation of Vagina (by Gynecological Examination)</measure>
    <time_frame>Screening &amp; Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Vaginal pH</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Percentage of Superficial Cells in the Maturation Index</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Estradiol Levels</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Luteinizing Hormone Levels</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Follicle Stimulating Hormone Levels</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Sex Hormone Binding Globulin Levels</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Atrophy</condition>
  <condition>Vaginal Diseases</condition>
  <arm_group>
    <arm_group_label>Subjects on placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will self-administer 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects on ospemifene 5 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will self-administer 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects on ospemifene 15 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will self-administer 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects on ospemifene 30 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will self-administer 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).</description>
    <arm_group_label>Subjects on placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ospemifene 5 mg</intervention_name>
    <description>1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).</description>
    <arm_group_label>Subjects on ospemifene 5 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ospemifene 15 mg</intervention_name>
    <description>1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).</description>
    <arm_group_label>Subjects on ospemifene 15 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ospemifene 30 mg</intervention_name>
    <description>1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).</description>
    <arm_group_label>Subjects on ospemifene 30 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Naturally or surgically menopausal

          -  Vaginal pH greater than 5.0

          -  5% or fewer superficial cells in maturation index of vaginal smear

        Exclusion Criteria:

          -  Evidence of endometrial hyperplasia, cancer or other pathology

          -  Abnormal PAP smear

          -  Uterine bleeding of unknown origin or uterine polyps

          -  Current vaginal infection requiring medication

          -  Use of hormonal medications

          -  Clinically significant abnormal gynecological findings other than signs of vaginal
             atrophy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <results_first_submitted>March 19, 2013</results_first_submitted>
  <results_first_submitted_qc>May 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 28, 2013</results_first_posted>
  <last_update_submitted>May 21, 2013</last_update_submitted>
  <last_update_submitted_qc>May 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <name_title>Shionogi Clinical Trials Administrator</name_title>
    <organization>Shionogi</organization>
  </responsible_party>
  <keyword>Menopausal symptoms</keyword>
  <keyword>Urogenital atrophy</keyword>
  <keyword>Vulvar and vaginal atrophy in postmenopausal women</keyword>
  <keyword>Vaginal atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 9 centers in Finland. First patient was enrolled on August 09, 2007 and last patient completed on February 11, 2008</recruitment_details>
      <pre_assignment_details>The study population included postmenopausal women 40 to 80 years of age with a diagnosis of vulvar and vaginal atrophy (VVA) assessed by the maturation index (MI) of vaginal smear and vaginal pH at baseline</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects on Placebo</title>
          <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Subjects on Ospemifene 5 mg/Day</title>
          <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Subjects on Ospemifene 15 mg/Day</title>
          <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Subjects on Ospemifene 30 mg/Day</title>
          <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects on Placebo</title>
          <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Subjects on Ospemifene 5 mg/Day</title>
          <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Subjects on Ospemifene 15 mg/Day</title>
          <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Subjects on Ospemifene 30 mg/Day</title>
          <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="30"/>
            <count group_id="B5" value="126"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="6.0"/>
                    <measurement group_id="B2" value="61.5" spread="5.6"/>
                    <measurement group_id="B3" value="63.4" spread="7.1"/>
                    <measurement group_id="B4" value="62.0" spread="6.8"/>
                    <measurement group_id="B5" value="62.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.6" spread="10.1"/>
                    <measurement group_id="B2" value="66.5" spread="10.6"/>
                    <measurement group_id="B3" value="68.7" spread="13.5"/>
                    <measurement group_id="B4" value="65.9" spread="7.4"/>
                    <measurement group_id="B5" value="67.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.609" spread="0.049"/>
                    <measurement group_id="B2" value="1.636" spread=".051"/>
                    <measurement group_id="B3" value="1.641" spread=".062"/>
                    <measurement group_id="B4" value="1.617" spread=".058"/>
                    <measurement group_id="B5" value="1.626" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.89" spread="3.95"/>
                    <measurement group_id="B2" value="24.78" spread="3.44"/>
                    <measurement group_id="B3" value="25.50" spread="4.99"/>
                    <measurement group_id="B4" value="25.28" spread="3.20"/>
                    <measurement group_id="B5" value="25.61" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol</title>
          <units>drinks/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" spread="1.9"/>
                    <measurement group_id="B2" value="1.8" spread="2.4"/>
                    <measurement group_id="B3" value="1.2" spread="1.7"/>
                    <measurement group_id="B4" value="1.5" spread="2.3"/>
                    <measurement group_id="B5" value="1.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear</title>
        <time_frame>12 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear</title>
          <population>ITT</population>
          <units>percentage of parabasal cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="30.2"/>
                    <measurement group_id="O2" value="-2.8" spread="33.2"/>
                    <measurement group_id="O3" value="-24.1" spread="36.7"/>
                    <measurement group_id="O4" value="-26.8" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of the Vaginal Smear</title>
        <time_frame>12 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of the Vaginal Smear</title>
          <population>ITT</population>
          <units>percentage of superficial cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.5" lower_limit="-3" upper_limit="5"/>
                    <measurement group_id="O2" value="0.9" spread="3.1" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O3" value="5.0" spread="9.1" lower_limit="-5" upper_limit="30"/>
                    <measurement group_id="O4" value="5.6" spread="10.3" lower_limit="-5" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Vaginal pH</title>
        <time_frame>12 weeks</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Vaginal pH</title>
          <population>ITT</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.91"/>
                    <measurement group_id="O2" value="-0.37" spread="0.83"/>
                    <measurement group_id="O3" value="-0.95" spread="1.02"/>
                    <measurement group_id="O4" value="-1.11" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Evaluation of Vagina (by Gynecological Examination)</title>
        <time_frame>Screening &amp; Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Placebo (Week 12)</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 5 mg/Day (Week 12)</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O6">
            <title>Subjects on Ospemifine 15 mg/Day (Week 12)</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O7">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O8">
            <title>Subjects on Ospemifene 30 mg/Day (Week 12)</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Evaluation of Vagina (by Gynecological Examination)</title>
          <population>ITT</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="29"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Petechiae-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="24.2"/>
                    <measurement group_id="O4" value="36.4"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="55.2"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Petechiae-Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="29.4"/>
                    <measurement group_id="O3" value="42.4"/>
                    <measurement group_id="O4" value="39.4"/>
                    <measurement group_id="O5" value="55.2"/>
                    <measurement group_id="O6" value="24.1"/>
                    <measurement group_id="O7" value="53.3"/>
                    <measurement group_id="O8" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Petechiae-Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="12.1"/>
                    <measurement group_id="O4" value="6.1"/>
                    <measurement group_id="O5" value="31.0"/>
                    <measurement group_id="O6" value="17.2"/>
                    <measurement group_id="O7" value="26.7"/>
                    <measurement group_id="O8" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Petechiae-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="8.8"/>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="15.2"/>
                    <measurement group_id="O5" value="3.4"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Petechiae-Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.4"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="14.7"/>
                    <measurement group_id="O3" value="6.1"/>
                    <measurement group_id="O4" value="15.2"/>
                    <measurement group_id="O5" value="13.8"/>
                    <measurement group_id="O6" value="37.9"/>
                    <measurement group_id="O7" value="6.7"/>
                    <measurement group_id="O8" value="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor-Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1"/>
                    <measurement group_id="O2" value="47.1"/>
                    <measurement group_id="O3" value="30.3"/>
                    <measurement group_id="O4" value="48.5"/>
                    <measurement group_id="O5" value="48.3"/>
                    <measurement group_id="O6" value="48.3"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor-Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="57.6"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="31.0"/>
                    <measurement group_id="O6" value="10.3"/>
                    <measurement group_id="O7" value="43.3"/>
                    <measurement group_id="O8" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="6.1"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="6.9"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pallor-Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.4"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="20.6"/>
                    <measurement group_id="O3" value="15.2"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="44.8"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability-Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="32.4"/>
                    <measurement group_id="O3" value="27.3"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="34.5"/>
                    <measurement group_id="O6" value="44.8"/>
                    <measurement group_id="O7" value="40.0"/>
                    <measurement group_id="O8" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability-Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="41.2"/>
                    <measurement group_id="O3" value="36.4"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="48.3"/>
                    <measurement group_id="O6" value="6.9"/>
                    <measurement group_id="O7" value="23.3"/>
                    <measurement group_id="O8" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="5.9"/>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="6.9"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="20.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Friability-Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.4"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal dryness in the mucosa-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="6.1"/>
                    <measurement group_id="O4" value="27.3"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="51.7"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal dryness in the mucosa-Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="41.2"/>
                    <measurement group_id="O3" value="21.2"/>
                    <measurement group_id="O4" value="36.4"/>
                    <measurement group_id="O5" value="41.4"/>
                    <measurement group_id="O6" value="37.9"/>
                    <measurement group_id="O7" value="43.3"/>
                    <measurement group_id="O8" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal dryness in the mucosa-Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="32.4"/>
                    <measurement group_id="O3" value="63.6"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="37.9"/>
                    <measurement group_id="O6" value="6.9"/>
                    <measurement group_id="O7" value="33.3"/>
                    <measurement group_id="O8" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal dryness in the mucosa-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="10.3"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="13.3"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal dryness in the mucosa-Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.4"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal redness in the mucosa-None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="20.6"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="39.4"/>
                    <measurement group_id="O5" value="17.2"/>
                    <measurement group_id="O6" value="51.7"/>
                    <measurement group_id="O7" value="10.0"/>
                    <measurement group_id="O8" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal redness in the mucosa-Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9"/>
                    <measurement group_id="O2" value="41.2"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="21.2"/>
                    <measurement group_id="O5" value="48.3"/>
                    <measurement group_id="O6" value="27.6"/>
                    <measurement group_id="O7" value="50.0"/>
                    <measurement group_id="O8" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal redness in the mucosa-Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="21.2"/>
                    <measurement group_id="O5" value="31.0"/>
                    <measurement group_id="O6" value="17.2"/>
                    <measurement group_id="O7" value="23.3"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal redness in the mucosa-Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="15.2"/>
                    <measurement group_id="O4" value="15.2"/>
                    <measurement group_id="O5" value="3.4"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal redness in the mucosa-Not done</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="3.4"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Vaginal pH</title>
        <time_frame>Week 4</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Vaginal pH</title>
          <population>ITT</population>
          <units>pH</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.59"/>
                    <measurement group_id="O2" value="-0.26" spread="0.68"/>
                    <measurement group_id="O3" value="-0.53" spread="0.83"/>
                    <measurement group_id="O4" value="-0.78" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Percentage of Superficial Cells in the Maturation Index</title>
        <time_frame>Week 4</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Percentage of Superficial Cells in the Maturation Index</title>
          <population>ITT</population>
          <units>percentage of superficial cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.7" lower_limit="-4" upper_limit="9"/>
                    <measurement group_id="O2" value="0.6" spread="2.9" lower_limit="-4" upper_limit="11"/>
                    <measurement group_id="O3" value="2.5" spread="5.6" lower_limit="-3" upper_limit="23"/>
                    <measurement group_id="O4" value="5.0" spread="10.7" lower_limit="-4" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Estradiol Levels</title>
        <time_frame>Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Estradiol Levels</title>
          <population>ITT</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.011"/>
                    <measurement group_id="O2" value="0.004" spread="0.015"/>
                    <measurement group_id="O3" value="-0.010" spread="0.026"/>
                    <measurement group_id="O4" value="-0.003" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Luteinizing Hormone Levels</title>
        <time_frame>Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Luteinizing Hormone Levels</title>
          <population>ITT</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="4.71"/>
                    <measurement group_id="O2" value="-2.89" spread="5.94"/>
                    <measurement group_id="O3" value="-0.34" spread="9.23"/>
                    <measurement group_id="O4" value="-3.78" spread="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Follicle Stimulating Hormone Levels</title>
        <time_frame>Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Follicle Stimulating Hormone Levels</title>
          <population>ITT</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.36" spread="20.41"/>
                    <measurement group_id="O2" value="-7.04" spread="10.80"/>
                    <measurement group_id="O3" value="-5.99" spread="23.07"/>
                    <measurement group_id="O4" value="-15.32" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Sex Hormone Binding Globulin Levels</title>
        <time_frame>Week 12</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Sex Hormone Binding Globulin Levels</title>
          <population>ITT</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="10.0"/>
                    <measurement group_id="O2" value="2.9" spread="12.2"/>
                    <measurement group_id="O3" value="6.3" spread="12.5"/>
                    <measurement group_id="O4" value="18.0" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index</title>
        <time_frame>Week 4</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects on Placebo</title>
            <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Subjects on Ospemifene 5 mg/Day</title>
            <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Subjects on Ospemifene 15 mg/Day</title>
            <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Subjects on Ospemifene 30 mg/Day</title>
            <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index</title>
          <population>ITT</population>
          <units>percentage of parabasal cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="24.1"/>
                    <measurement group_id="O2" value="-0.6" spread="23.8"/>
                    <measurement group_id="O3" value="-19.7" spread="27.0"/>
                    <measurement group_id="O4" value="-22.0" spread="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subjects on Placebo</title>
          <description>Subjects took 1 placebo tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Subjects on Ospemifene 5 mg/Day</title>
          <description>Subjects took 1 ospemifene 5 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Subjects on Ospemifene 15 mg/Day</title>
          <description>Subjects took 1 ospemifene 15 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Subjects on Ospemifene 30 mg/Day</title>
          <description>Subjects took 1 ospemifene 30 mg tablet daily (in the morning with food) for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707 ext 1454</phone>
      <email>shionogiclintrialsadmin@shionogi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

